Table 4 TE grade ≥ 3 infections during the first 4 months of high- and low-risk populations in various studies

From: A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Trial

Grade ≥ 3 infections, %

P-value*low risk vs. high risk

RR (95% CI)

NNT

 

Low risk (−3 to 1 points)

High risk (2 to 5 points)

   

MM-020 (N = 1 369)a

7.0

24.0

8.19 × 10−19

3.43 (2.57–4.59)

8.3

Rd pooled (n = 918)

7.4

24.9

2.7 × 10−13

3.37 (2.39–4.76)

8.0

MPT (n = 451)

6.2

22.4

9.15 × 10−7

3.63 (2.11–6.24)

8.9

MM-015 (n = 384)a

6.3

12.9

0.0552

2.05 (1.07–3.92)

15.5

MM-009/10 (n = 404)a

17.1

35.7

7.69 × 10−4

2.09 (1.41–3.10)

5.6

MM-003 (n = 222)a

30.3

63.3

2.21 × 10−6

2.09 (1.54–2.83)

3.2

  1. MPT melphalan, prednisone, and thalidomide, NNT number needed to treat, Rd cont lenalidomide plus low-dose dexamethasone until disease progression, Rd18 lenalidomide plus low-dose dexamethasone for 18 cycles, Rd pooled Rd cont and Rd18 patients combined, RR relative risk, TE treatment emergent
  2. *P-value computed with χ2 test
  3. a Patients with missing data for ≥ 1 of the variables selected by the multivariate logistic regression were excluded from the high-/low-risk definition
Back to article page